A month after reporting that its RAS inhibitor daraxonrasib doubled survival in advanced pancreatic cancer, Truist said ...
The late-stage miss shakes analyst confidence in Regeneron’s clinical execution, according to BMO Capital Markets, also ...
Last month, Revolution Medicines’ RAS inhibitor doubled survival in a Phase 3 pancreatic cancer trial. On the biotech’s heels are Immuneering, Actuate Therapeutics, Erasca and more, looking to improve ...
California life sciences jobs declined 1.8% last year, according to the new California Life Sciences sector report. While ...
While Biogen’s tau-targeting therapy didn’t demonstrate improvement on a dementia severity scale, the company touted ...
Just a few days after FDA Commissioner Makary resigned, ally Tracy Beth Høeg is also leaving the agency. Her departure comes ...
Isomorphic Labs, which hasn’t yet disclosed a molecule or reached the clinic, breaks the recent trend of investors putting ...
Rina-S is the last candidate standing from Genmab’s $1.8 billion ProfoundBio acquisition two years ago, with the Danish ...
In a letter to President Donald Trump, a group of biotech executives recommended former cancer regulator Richard Pazdur to ...
Renewed pharma interest in GPCR biology and radioligand therapies is drawing attention to functional peptide screening ...
CREATE Medicines is working on a clinical-stage pipeline for cancer, while its autoimmune programs are still in preclinical ...
Despite seeing some regain, patients in two trials maintained most of their weight loss after switching to either Foundayo or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results